INDIAHEALTH policyHEALTH services accessibilityGOVERNMENT regulationMEDICAL protocolsPOLICY sciencesRARE diseasesHEALTH care rationingMore than 8% of the global population is affected by a rare disease and >50% affected are children (30% of whom will die before 5 years). There ...
Rare disease (RD) management and orphan drug development in India face various hurdles regarding the implementation and adoption of comprehensive policies, lack of dedicated regulatory frameworks, and absence of epidemiological data. Current rare disease policy focuses more on strengthening the diagnostics ...
7 comprehensive market analysis studies and industry reports on the Rare Disease Drugs sector, offering an industry overview with historical data since 2019 and forecasts up to 2030. This includes a detailed market research of 67 research companies, enri
Join the 14th World Congress on Rare Diseases and Orphan Drugs, June 2-3, 2025, in Amsterdam. Explore breakthroughs in research, treatment, and innovation to transform rare disease care globally.
Policy for Comprehensive Care for People of Rare Disease in 2014, a national plan with the aim to decrease morbidity and mortality of RD, improving the care of people with RD in the public health system are described. The process that finally led to such policy took over a decade, moving ...
Prof. Ramaiah Muthyala, President & CEO, Indian Organization for Rare Diseases; said,in 2021, the ministry of health and family welfare drafted the national policy for rare disease treatment. The policy is inadequate to serve the needs of rare disease patients because ...
Rare diseases, an emerging global public health priority, require an evidence-based estimate of the global point prevalence to inform public policy. We used the publicly available epidemiological data in the Orphanet database to calculate such a prevalen
India–UK relations are both wide ranging and robust, encompassing a broad vision for the future supported by a concrete and comprehensive road map for bilateral and globa... PS Chauhan 被引量: 0发表: 2021年 Brexit and trade policy: an analysis of the governance of UK trade policy and ...
The global rare disease genetic testing market size is expected to reach USD 2.52 billion by 2030, registering a CAGR of 13.94% over the forecast period, according to a new report by Grand View Research, Inc.
This is mainly owing to the increase in awareness and diagnosis abilities. Furthermore, the introduction of policies and frameworks to promote disease management will offer lucrative opportunities in this region. For instance, in India, in March 2021, an inclusive National Policy for Rare Diseases ...